Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial. (January 2018)

• Record Type: Journal Article
• Authors: Rieu, Isabelle; Degos, Bertrand; Castelnovo, Giovanni; Vial, Christophe; Durand, Elodie; Pereira, Bruno; Simonetta-Moreau, Marion; Sangla, Sophie; Fluchère, Frédérique; Guehl, Dominique; Burbaud, Pierre; Geny, Christian; Gayraud, Dominique; Ory-Magne, Fabienne; Bouhour, Françoise; Llinares, Elisabeth; Derost, Philippe; Marques, Ana; Durif, Franck
• Is Part Of: Parkinsonism & related disorders. Volume 46(2018)
• Page Start: 9
• Page End: 15
• Publication Date: 2018-01
• Subjects: Foot dystonia -- Parkinson's disease -- Botulinum toxin -- Clinical trials randomized controlled; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2017.10.009
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Introduction: Plantar flexion of toe dystonia is very painful and leads to difficulties in walking. The objective of this study was to investigate the effect of incobotulinum toxin A (Xeomin) in the treatment of this type of dystonia in parkinsonian patients, using a randomized, double blind, placebo-controlled trial. Methods: 45 parkinsonian patients with painful dystonic plantar flexion of toes were injected either with incobotulinum toxin A (Btx group), or with placebo in two muscle targets: the Flexor digitorum longus and the Flexor digitorum brevis . Three groups were compared: the first group received placebo in the Flexor digitorum longus and 100UI of Btx in the Flexor digitorum brevis (n = 16); the second group received 100 UI of Btx in the Flexor digitorum longus and placebo in the Flexor digitorum brevis (n = 13); and the third group, 2 injections of placebo (n = 16). The patients were injected in the same way twice with an interval of 3 months. The primary endpoint was measured six weeks after injections with the Clinical Global Impression (CGI) of change. Dystonia severity and associated pain were also assessed. Results: Mean CGI was improved in the Btx group compared to the placebo group ( P = 0.039). A significant reduction of pain and dystonia severity were observed in patients treated with Btx compared to baseline but no improvement was noted when compared to placebo group. No difference of efficacy was highlighted between the two injection sites. Conclusions: Btx injections are effective for improving clinical state of parkinsonian patients with plantar flexion of toe dystonia. Highlights: Plantar flexion of toe dystonia (PFTD) is painful and leads to difficulties in walking. Efficacy of Btx injections was tested in parkinsonian patients with PFTD. Btx injections are effective for improving clinical state of patients with PFTD. Efficacy is similar whatever the muscle injected ( Flexor digitorum brevis or longus ).